News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Hossein Borghaei, DO, MS, Talks Current Research Trends in Lung Cancer

Nov 21, 2021
Hossein Borghaei, DO, MS

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about coming research involving immunotherapy for patients with lung cancer.

CancerNetwork® spoke with Hossein Borghaei, DO, MS, of the Fox Chase Cancer Center and Thoracic Malignancies Chair for the journal ONCOLOGY®, about how investigators are gaining more information to help treat patients receiving immunotherapy. Borghaei also emphasizes the need for more insight regarding molecular information for understanding which patients benefit from treatment. 

Transcript:

There are a lot of data coming out that are going to be relevant, and whether we can call them research trends right now or not is a bit difficult. What I mean by that is in a patient population for whom we use immunotherapy, or patients who don’t have molecularly driven tumors, the big question has always been how do you identify patients who are truly benefiting from immunotherapy? We know PD-L1 can be one biomarker, but we all realize that it is not as perfect a biomarker as we want it to be. We see patients with high PD-L1 who don’t respond necessarily all that well, or patients with low PD-L1 expression will respond well.

There’s a lot of work being done regarding molecular determinants of response in immunotherapy, for instance in genes like STK11 or KEAP1. That has a couple of implications, one emphasizes the fact that we do need to participate in these broader next-generation sequencing panels for our molecular testing because these computations might not appear to be significant right now. However, 6 months from now, there could be publications that can help us figure out whether there is relevance to some of these, so that’s number 1.

Number 2, as we gain more molecular information and genomic data on lung tumors, we might be able to find other signatures that would help us better determine whether somebody is going to benefit from checkpoint inhibitors or not. That’s a trend that I have seen, and I think there are more data coming on that. We are also looking into farther defining the resistance mechanisms that we see with the currently available checkpoint inhibitors. We tend to divide those patients into 2 categories. We have patients who, unfortunately, have virtually no response to checkpoint inhibitors, meaning you do the first couple of CT scans and the cancer is already progressing. These are what we have labeled primary-refractory patients. In the other group, we have patients who do seem to benefit from checkpoint inhibitors, at least initially, but then, unfortunately, the cancer progresses. Those are patients who we think have developed within the tumor microenvironment a secondary resistant mechanism. When you think about it, even logically, there has to be 2 different tumor [types] and there has to be something [done] about that. What determines primary from secondary refractory [disease] is a bit of an unknown, but there is a tremendous amount of research [that is currently] ongoing.

What to do about these tumors might be different because, again, if the mechanism of resistance is different, you can imagine that a tumor that is. [If a tumor is] primary refractory to checkpoint inhibitors, it might need a different combination or approach than a tumor that initially responded and now is progressing. I could be wrong, you could find something that works in both categories, but logically thinking about them, those mechanisms should be different.

That’s a very robust area of investigation. The difficulty here is that the data sets are somewhat small, there are a couple hundred patients from one center and a couple hundred from another center, and sometimes the data don’t agree. Putting these things together and trying to come up with a comprehensive look is where we are right now. It’s definitely a growing body of literature concentrating on that, and I think it definitely deserves attention.

Related Videos
In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Experts on lung cancer
Expert on lung cancer
Expert on lung cancer
Expert on lung cancer
Experts on lung cancer
Expert on lung cancer
Expert on lung cancer
Expert on lung cancer
Experts on lung cancer
Related Content

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

May 25th 2023

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

September 18th 2018

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

August 1st 2018

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

May 25th 2023

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

September 18th 2018

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

August 1st 2018

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

May 25th 2023

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

September 18th 2018

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

August 1st 2018

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022
Related Content

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer | Image Credit: © appledesign - stock.adobe.com.

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

May 25th 2023
Article

Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy.


Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

September 18th 2018
Podcast

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.


FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

March 4th 2023
Article

“Upon activating a fluorescent lamp, the cancer tissue glows very brightly, like stars against a black sky, and enables us to see exactly where the tumor tissue was.”


We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

August 1st 2018
Podcast

Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.


OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

January 13th 2023
Article

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.


An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

December 20th 2022
Article

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.